Who we are

Movetis is a European specialty GI company that is focused on improving the lives of millions of patients – both adults and children – by discovering, developing and commercialising innovative treatments targeting GI conditions with a high unmet medical need. Movetis NV was founded in Belgium in November 2006 as a spin-off of Johnson & Johnson.

Movetis has a broad portfolio of GI products: Resolor® (prucalopride) is approved in the European Economic Area for the indication “symptomatic treatment of chronic constipation in women in whom laxatives fail to provide adequate relief”. The marketing authorisation application is currently under review in Switzerland. Two products are in Phase II development and Movetis has two prioritised compounds in preclinical development, all addressing important GI areas including ascites, paediatric reflux, refractory GORD (gastroesophageal reflux disease) and severe forms of irritable bowel syndrome. In addition, Movetis has rights to a large library of qualified lead compounds with potential for development in different GI indications and access to know how for compounds in secretory diarrhoea. The current portfolio is licensed from Janssen Pharmaceutica NV, Belgium and Ortho-McNeil Pharmaceutical Inc., two Johnson & Johnson companies.

Europe is Movetis' home market. The Company is based in Turnhout, Belgium, and has recently set up commercial organisations in Germany and the UK, with the intention to expand this to France and the Benelux in a later stage. In parallel, Movetis seeks to enter into partnership agreements to cover other geographical markets, with a first priority for Europe.

In December 2009, Movetis completed its Initial Public Offering (IPO) on Euronext Brussels (MOVE). In conjunction with its IPO, the Company raised €97.75 million to support its corporate strategy.